Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mithramycin A chemogenomic profile

ABSTRACT: Mithramycin A in known to bind DNA but its exact cellular mechanism of action is still unclear. We used Affymatrix GenFlex_Tag_16K_V2 microarrays to profile sensitivity of genetically barcoded S. cerevisiae gene deletion strains to mithramycin A

ORGANISM(S): Saccharomyces cerevisiae

PROVIDER: GSE122458 | GEO | 2020/11/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Mithramycin A chemogenomic profile

Project description:Mithramycin A chemogenomic profile

| PRJNA505281 | ENA

Ewing Sarcoma cell lines treated with mithramycin

Project description:The study aims to define gene expression changes associated with mithramycin treatment of Ewing Sarcoma cell lines. The data consist of 12 arrays. Two cell lines, TC71 and TC32, were treated with solvent control or with mithramycin, and RNA was extracted at 6 hours. Three biological replicates per cell line/treatment.

2011-04-18 | E-GEOD-25127 | biostudies-arrayexpress

Mithramycin Depletes Sp1 and Activates p53 to Mediate Senescence and Apoptosis of Pleural Mesothelioma Cells

Project description:We used microarrays to detail the global gene expression of mithramycin treated cells, xenografts and sp1 depleted cells with p53 overexpression. MPM cells and xenografts were treated with mithramycin or SP1 depleted/p53 overexpressed MPM cells were selected for RNA extraction and hybridization on Affymetrix microarrays. We sought to see the invitro and invivo effect of mithramycin (pharmacological model) and depletion of SP1 and overexpression of p53 (genetic model).

2015-01-07 | E-GEOD-64738 | biostudies-arrayexpress

Ewing Sarcoma cell lines treated with mithramycin

Project description:The study aims to define gene expression changes associated with mithramycin treatment of Ewing Sarcoma cell lines.

2011-04-18 | GSE25127 | GEO

Human Chronic Lymphocytic Leukaemia cells: Untreated vs mithramycin-treated

Project description:Transcriptional profiling of primary human malignant B cells from patients with chronic lymphocytic leukaemia (CLL), comparing untreated CLL cells with CLL cells that have been treated 24h with 200nM mithramycin. Mithramycin intercalates into GC-rich regions of DNA to inhibit binding of the transcription factor SP1. The goal of this experiment is to gain understanding of the genes regulated by SP1 in primary CLL cells.

2022-12-14 | GSE210348 | GEO

Mithramycin Depletes Sp1 and Activates p53 to Mediate Senescence and Apoptosis of Pleural Mesothelioma Cells

Project description:We used microarrays to detail the global gene expression of mithramycin treated cells, xenografts and sp1 depleted cells with p53 overexpression.

2015-01-07 | GSE64738 | GEO

Genome-wide analysis of the effects of the novel mithramycin analogue DIG-MSK on human A2780 ovarian carcinoma cells

Project description:The effects of demycarosyl-3D-M-NM-2-D-digitoxosyl-mithramycin SK (DIG-MSK; EC-8042), a novel analogue of the antitumor antibiotic mithramycin A, on gene transcription were examined in human A2780 ovarian carcinoma cells. DIG-MSK down-regulated a different set of genes depending on the drug concentration. Moreover, several genes were significantly up-regulated. These results are rationalized in terms of DIG-MSK competition with Sp1 transcription factor for binding to consensus C/G-rich tracts encompassed in gene promoters. Human A2780 ovarian carcinoma cells were treated with either 8 nM or 80 nM DIG-MSK for 24 h, and RNA was extracted from treated cells as well as from untreated (control) cells.

2014-08-13 | E-GEOD-46926 | biostudies-arrayexpress

Genome-wide analysis of the effects of the novel mithramycin analogue DIG-MSK on human A2780 ovarian carcinoma cells

Project description:The effects of demycarosyl-3D-β-D-digitoxosyl-mithramycin SK (DIG-MSK; EC-8042), a novel analogue of the antitumor antibiotic mithramycin A, on gene transcription were examined in human A2780 ovarian carcinoma cells. DIG-MSK down-regulated a different set of genes depending on the drug concentration. Moreover, several genes were significantly up-regulated. These results are rationalized in terms of DIG-MSK competition with Sp1 transcription factor for binding to consensus C/G-rich tracts encompassed in gene promoters.

2014-08-13 | GSE46926 | GEO

Saccharomyces cerevisiae deletion collections chemogenomic screen with sr7575

Project description:Growth assay in the presence of a toxic chemical (sr7575) that uses the barcoded collections of yeast gene deletions (haploid, diploid, DamP) to identify deletion strains that are hypersensitive to the drug.

2015-12-09 | GSE60934 | GEO

Gene expression profiling of sarcoma cells treated with mithramycin A (MTA), nano-encapsulated MTA or MTA-analogs

Project description:This study was designed to gain insight about the mechanisms involved in the anti-tumor effects of mithramycin A (MTA) and the MTA analog EC-8042 in sarcoma cells. In addition, we also studied whether this molecular features could be influenced by the nano-encapsulation of MTA.

2021-03-30 | GSE161616 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data